Granules India Bags Sole First-to-File ANDA Status for Generic Version of Lumryz

Synopsis: A regulatory filing was announced this week, having secured Sole First-to-File status for the generic version of a narcolepsy drug; the news adds to a complex-generics track record that is starting to show up in margins, even as the stock’s valuation already prices in a good deal of that promise.

Shares of a vertically integrated pharmaceutical manufacturer came into focus after the company announced it had secured Sole First-to-File status for its Abbreviated New Drug Application covering Sodium Oxybate Extended-Release for Oral Suspension, the generic equivalent of a branded narcolepsy treatment. This is the company’s second such designation, following an earlier Sole First-to-File win for an extended-release ADHD medication.

With a market capitalisation of Rs. 21,028.05 crore, the shares of Granules India were trading at Rs. 848.60 per share, up around 1.78 percent from its previous closing price of roughly Rs. 848.20 apiece. The stock is trading at a P/E of 34.72.

What Was Announced

Granules India said it has secured Sole First-to-File status for its ANDA on Sodium Oxybate Extended-Release for Oral Suspension, positioning it as the generic equivalent of LUMRYZ, a branded treatment for cataplexy and excessive daytime sleepiness in narcolepsy patients. Sole First-to-File status under US ANDA rules generally means the company was first to submit a substantially complete application with a Paragraph IV certification challenging the originator’s patents, and being the sole such filer typically carries eligibility for a period of market exclusivity once the ANDA is approved.

This follows the company’s earlier Sole First-to-File designation for Amphetamine Extended-Release Tablets, the generic equivalent of Dyanavel XR, indicating a deliberate push into differentiated, harder-to-replicate generic formulations rather than commodity-style APIs.

It is worth being precise about what this status does and does not guarantee. Sole First-to-File is a procedural designation, not marketing approval; the ANDA still needs to clear USFDA review, and Paragraph IV filings routinely trigger patent litigation from the originator that can delay any eventual launch by years rather than months. Retail investors should treat this as an option on a future revenue stream rather than a near-term earnings event. That said, the strategic signal is real: complex generics with exclusivity potential typically carry far better pricing and margins than standard generics, and a second such win in as many years suggests the R&D pipeline behind this strategy is producing results rather than being a one-off.

The financial backdrop gives this some added credibility. Operating margin in the March 2026 quarter came in at 24 percent, the best in the last three years of quarterly data, up from 19-21 percent through most of FY25. Full-year FY26 revenue grew 19.7 percent to Rs. 5,366 crore and net profit grew 18.5 percent to Rs. 595 crore, both meaningfully faster than the company’s own trailing five-year averages of 11 percent revenue growth and roughly flat profit growth. The market has already rewarded this reacceleration; the stock is up around 69 percent over the past year which means a good part of the complex-generics narrative, including this ANDA win, is arguably already reflected in the price.

Two things temper enthusiasm on the numbers side. First, working capital has deteriorated steadily: inventory days have nearly doubled from 182 in FY23 to 326 in FY26, pushing the cash conversion cycle out from 135 days to 256 days over the same period. For a manufacturer running ten facilities across three countries, this could reflect deliberate stocking ahead of new product launches, but it is also the kind of trend that ties up cash and deserves tracking in the results due later this quarter. The company’s trading window has in fact been closed since July 1 pending Q1 FY27 results.

Second, promoter holding has fallen from roughly 42 percent to 38 percent over the past three years, a gradual but steady decline that shareholders should keep an eye on, alongside a screener-flagged possibility that the company may be capitalising some interest costs rather than expensing them, which can understate near-term costs relative to reported profit.

On the ownership side, the picture is more constructive: FII holding has climbed from about 13 percent in mid-2025 to 17.5 percent as of June 2026, while the number of shareholders has risen past 1.69 lakh, suggesting broadening institutional and retail interest rather than a stock rallying on thin, concentrated buying. Free cash flow for FY26 came in at Rs. 239 crore against operating cash flow of Rs. 793 crore, reflecting continued heavy capital expenditure as the company builds out capacity, a reasonable trade-off if the complex-generics pipeline, including this ANDA, eventually converts into approved, exclusive products.

Business Overview

Granules India, incorporated in 1991 and headquartered in Hyderabad, is a vertically integrated pharmaceutical company spanning APIs, pharmaceutical formulation intermediates, finished dosages and peptide CDMO services, with ten manufacturing facilities across India, the US and Switzerland and regulatory approvals from USFDA, EU GMP and other global authorities. For FY26, consolidated revenue rose 19.7 percent to Rs. 5,366 crore and net profit rose 18.5 percent to Rs. 595 crore, with return on equity of 13.7 percent.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Granules India Bags Sole First-to-File ANDA Status for Generic Version of Lumryz appeared first on Trade Brains.